The Side Effect Profile of ZEJULA Is Well-Characterized1
Maintenance Treatment of Patients With Recurrent Ovarian Cancer Who Are in Complete or Partial Response to Platinum-Based Chemotherapy
Treatment of Patients With Advanced Ovarian Cancer After Three or More Chemotherapies Whose Cancer Is Associated With HRD+ Status
Reference: 1. ZEJULA (niraparib) [package insert]. Waltham, MA: GSK, Inc; October 2019.